Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CXCL2

Gene summary for CXCL2

Gene summary.

Gene information	Species	Human
	Gene symbol	CXCL2
	Gene ID	2920
	Gene name	C-X-C motif chemokine ligand 2
	Gene Alias	CINC-2a
	Cytomap	4q13.3
	Gene Type	protein-coding
	GO ID	GO:0002237
	UniProtAcc	A0A024RDD9

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2920	CXCL2	GSM4909280	Human	Breast	Precancer	1.26e-04	7.82e-01	0.0305
2920	CXCL2	GSM4909281	Human	Breast	IDC	1.32e-40	-9.90e-01	0.21
2920	CXCL2	GSM4909282	Human	Breast	IDC	1.73e-25	-8.82e-01	-0.0288
2920	CXCL2	GSM4909285	Human	Breast	IDC	2.32e-33	-9.67e-01	0.21
2920	CXCL2	GSM4909286	Human	Breast	IDC	2.63e-52	-1.03e+00	0.1081
2920	CXCL2	GSM4909287	Human	Breast	IDC	2.97e-19	-7.76e-01	0.2057
2920	CXCL2	GSM4909289	Human	Breast	IDC	5.36e-06	-8.94e-01	0.1064
2920	CXCL2	GSM4909290	Human	Breast	IDC	1.31e-21	-9.06e-01	0.2096
2920	CXCL2	GSM4909291	Human	Breast	IDC	1.13e-19	-9.48e-01	0.1753
2920	CXCL2	GSM4909292	Human	Breast	IDC	3.92e-04	-9.72e-01	0.1236
2920	CXCL2	GSM4909293	Human	Breast	IDC	2.77e-31	-9.00e-01	0.1581
2920	CXCL2	GSM4909294	Human	Breast	IDC	1.41e-47	-9.95e-01	0.2022
2920	CXCL2	GSM4909295	Human	Breast	IDC	3.50e-02	-4.90e-01	0.0898
2920	CXCL2	GSM4909296	Human	Breast	IDC	1.13e-31	-9.22e-01	0.1524
2920	CXCL2	GSM4909297	Human	Breast	IDC	3.04e-26	-6.72e-01	0.1517
2920	CXCL2	GSM4909298	Human	Breast	IDC	1.99e-42	-9.86e-01	0.1551
2920	CXCL2	GSM4909301	Human	Breast	IDC	3.59e-46	-1.02e+00	0.1577
2920	CXCL2	GSM4909302	Human	Breast	IDC	3.44e-32	-9.38e-01	0.1545
2920	CXCL2	GSM4909304	Human	Breast	IDC	8.65e-48	-1.03e+00	0.1636
2920	CXCL2	GSM4909306	Human	Breast	IDC	4.60e-23	-8.08e-01	0.1564

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00975297	Breast	Precancer	myeloid leukocyte migration	34/1080	220/18723	1.42e-07	7.82e-06	34
GO:00509006	Breast	Precancer	leukocyte migration	47/1080	369/18723	2.82e-07	1.39e-05	47
GO:00305956	Breast	Precancer	leukocyte chemotaxis	34/1080	230/18723	4.16e-07	1.89e-05	34
GO:00603266	Breast	Precancer	cell chemotaxis	41/1080	310/18723	5.99e-07	2.55e-05	41
GO:00716217	Breast	Precancer	granulocyte chemotaxis	23/1080	125/18723	6.73e-07	2.77e-05	23
GO:00975307	Breast	Precancer	granulocyte migration	24/1080	148/18723	4.04e-06	1.26e-04	24
GO:00305937	Breast	Precancer	neutrophil chemotaxis	19/1080	103/18723	5.94e-06	1.71e-04	19
GO:00022378	Breast	Precancer	response to molecule of bacterial origin	43/1080	363/18723	6.05e-06	1.72e-04	43
GO:00324968	Breast	Precancer	response to lipopolysaccharide	41/1080	343/18723	7.94e-06	2.17e-04	41
GO:19902665	Breast	Precancer	neutrophil migration	20/1080	122/18723	2.13e-05	4.99e-04	20
GO:00197307	Breast	Precancer	antimicrobial humoral response	19/1080	122/18723	7.02e-05	1.40e-03	19
GO:00618446	Breast	Precancer	antimicrobial humoral immune response mediated by antimicrobial peptide	14/1080	79/18723	1.53e-04	2.61e-03	14
GO:00712227	Breast	Precancer	cellular response to lipopolysaccharide	25/1080	209/18723	4.41e-04	5.85e-03	25
GO:00712167	Breast	Precancer	cellular response to biotic stimulus	28/1080	246/18723	4.67e-04	6.14e-03	28
GO:00712197	Breast	Precancer	cellular response to molecule of bacterial origin	25/1080	221/18723	1.00e-03	1.12e-02	25
GO:007162111	Breast	IDC	granulocyte chemotaxis	26/1434	125/18723	2.36e-06	9.30e-05	26
GO:005090011	Breast	IDC	leukocyte migration	54/1434	369/18723	3.10e-06	1.15e-04	54
GO:009752911	Breast	IDC	myeloid leukocyte migration	37/1434	220/18723	4.65e-06	1.62e-04	37
GO:003059511	Breast	IDC	leukocyte chemotaxis	38/1434	230/18723	5.36e-06	1.76e-04	38
GO:003059311	Breast	IDC	neutrophil chemotaxis	22/1434	103/18723	8.82e-06	2.50e-04	22

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0513414	Breast	Precancer	Legionellosis	19/684	57/8465	4.62e-08	9.12e-07	6.98e-07	19
hsa0516718	Breast	Precancer	Kaposi sarcoma-associated herpesvirus infection	36/684	194/8465	1.68e-06	2.53e-05	1.94e-05	36
hsa0541718	Breast	Precancer	Lipid and atherosclerosis	37/684	215/8465	7.64e-06	9.29e-05	7.12e-05	37
hsa0465716	Breast	Precancer	IL-17 signaling pathway	20/684	94/8465	4.74e-05	4.54e-04	3.48e-04	20
hsa0532312	Breast	Precancer	Rheumatoid arthritis	19/684	93/8465	1.30e-04	1.14e-03	8.73e-04	19
hsa051206	Breast	Precancer	Epithelial cell signaling in Helicobacter pylori infection	14/684	70/8465	1.21e-03	7.99e-03	6.12e-03	14
hsa0513415	Breast	Precancer	Legionellosis	19/684	57/8465	4.62e-08	9.12e-07	6.98e-07	19
hsa0516719	Breast	Precancer	Kaposi sarcoma-associated herpesvirus infection	36/684	194/8465	1.68e-06	2.53e-05	1.94e-05	36
hsa0541719	Breast	Precancer	Lipid and atherosclerosis	37/684	215/8465	7.64e-06	9.29e-05	7.12e-05	37
hsa0465717	Breast	Precancer	IL-17 signaling pathway	20/684	94/8465	4.74e-05	4.54e-04	3.48e-04	20
hsa0532313	Breast	Precancer	Rheumatoid arthritis	19/684	93/8465	1.30e-04	1.14e-03	8.73e-04	19
hsa0512013	Breast	Precancer	Epithelial cell signaling in Helicobacter pylori infection	14/684	70/8465	1.21e-03	7.99e-03	6.12e-03	14
hsa0513422	Breast	IDC	Legionellosis	19/867	57/8465	1.89e-06	3.07e-05	2.29e-05	19
hsa0516723	Breast	IDC	Kaposi sarcoma-associated herpesvirus infection	38/867	194/8465	5.87e-05	5.96e-04	4.46e-04	38
hsa0532321	Breast	IDC	Rheumatoid arthritis	21/867	93/8465	3.69e-04	3.15e-03	2.36e-03	21
hsa0512022	Breast	IDC	Epithelial cell signaling in Helicobacter pylori infection	16/867	70/8465	1.56e-03	1.13e-02	8.42e-03	16
hsa0541724	Breast	IDC	Lipid and atherosclerosis	35/867	215/8465	3.67e-03	2.29e-02	1.71e-02	35
hsa0465721	Breast	IDC	IL-17 signaling pathway	18/867	94/8465	6.39e-03	3.30e-02	2.47e-02	18
hsa0513432	Breast	IDC	Legionellosis	19/867	57/8465	1.89e-06	3.07e-05	2.29e-05	19
hsa0516733	Breast	IDC	Kaposi sarcoma-associated herpesvirus infection	38/867	194/8465	5.87e-05	5.96e-04	4.46e-04	38

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand	Receptor	LRpair	Pathway	Tissue	Disease Stage
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Breast	DCIS
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Breast	Healthy
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Breast	IDC
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Breast	Precancer
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Cervix	ADJ
CXCL2	CXCR2	CXCL2_CXCR2	CXCL	Cervix	ADJ
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Cervix	CC
CXCL2	CXCR1	CXCL2_CXCR1	CXCL	Cervix	CC
CXCL2	CXCR2	CXCL2_CXCR2	CXCL	Cervix	CC
CXCL2	CXCR1	CXCL2_CXCR1	CXCL	Cervix	Healthy
CXCL2	CXCR2	CXCL2_CXCR2	CXCL	Cervix	Healthy
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Cervix	Precancer
CXCL2	CXCR1	CXCL2_CXCR1	CXCL	Cervix	Precancer
CXCL2	CXCR2	CXCL2_CXCR2	CXCL	Cervix	Precancer
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Endometrium	ADJ
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Endometrium	AEH
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Endometrium	EEC
CXCL2	CXCR2	CXCL2_CXCR2	CXCL	Endometrium	EEC
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Endometrium	Healthy
CXCL2	ACKR1	CXCL2_ACKR1	CXCL	Esophagus	ESCC

Page: 1 2 3

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CXCL2

SNV

Missense_Mutation

novel

c.217G>A

p.Glu73Lys

p.E73K

P19875

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CXCL2

SNV

Missense_Mutation

c.16N>T

p.Leu6Phe

p.L6F

P19875

protein_coding

tolerated_low_confidence(0.4)

benign(0.346)

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

CXCL2

SNV

Missense_Mutation

novel

c.297N>T

p.Lys99Asn

p.K99N

P19875

protein_coding

deleterious(0)

probably_damaging(0.992)

TCGA-AA-A00N-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

CXCL2

SNV

Missense_Mutation

novel

c.217N>A

p.Glu73Lys

p.E73K

P19875

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AJ-A3EL-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

CXCL2

SNV

Missense_Mutation

rs758440195

c.149N>G

p.Gln50Arg

p.Q50R

P19875

protein_coding

tolerated(0.18)

benign(0.026)

TCGA-AP-A059-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

CXCL2

SNV

Missense_Mutation

rs755316953

c.165G>T

p.Lys55Asn

p.K55N

P19875

protein_coding

deleterious(0.03)

probably_damaging(0.982)

TCGA-AP-A1E0-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

paclitaxel

CXCL2

SNV

Missense_Mutation

c.292G>A

p.Glu98Lys

p.E98K

P19875

protein_coding

tolerated(0.09)

benign(0.009)

TCGA-B5-A11E-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

CXCL2

SNV

Missense_Mutation

novel

c.208N>A

p.Ala70Thr

p.A70T

P19875

protein_coding

tolerated(0.55)

benign(0.027)

TCGA-EO-A22R-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

CXCL2

SNV

Missense_Mutation

novel

c.121C>A

p.Leu41Met

p.L41M

P19875

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-EO-A22U-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

CXCL2

insertion

Frame_Shift_Ins

novel

c.202dupC

p.His68ProfsTer27

p.H68Pfs*27

P19875

protein_coding

TCGA-AP-A051-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
2920	CXCL2	DRUGGABLE GENOME		BCG	BCG VACCINE	18217952
2920	CXCL2	DRUGGABLE GENOME		NEUROTROPHIC FACTOR		15194436
2920	CXCL2	DRUGGABLE GENOME		IL-13		16439363
2920	CXCL2	DRUGGABLE GENOME		CYCLOSPORIN A		7490125
2920	CXCL2	DRUGGABLE GENOME		BB-94	BATIMASTAT	18477053
2920	CXCL2	DRUGGABLE GENOME		Laquinamod
2920	CXCL2	DRUGGABLE GENOME		STAUROSPORINE	STAUROSPORINE	10354507
2920	CXCL2	DRUGGABLE GENOME		BFGF		15194436
2920	CXCL2	DRUGGABLE GENOME		DEXTRAN SULFATE SODIUM		18542050
2920	CXCL2	DRUGGABLE GENOME		TPA	ALTEPLASE	18199827

Page: 1 2